drugset / Trial / NCT01652885

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

NCT01652885

Phase 1/2 Completed 23 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.

Timeline

Start
2012-07
Primary completion
2012-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Crisaborole Small molecule 2 % Topical

Indications